Press Release: National Science Foundation Awards Additional $500,000 to DMC Biotechnologies, Inc. For Commercialization


[Boulder, CO] November 18, 2019 – The US National Science Foundation (NSF) has awarded an additional $500,000 to DMC through its Small Business Innovation Research (SBIR) Phase IIB program. This is in addition to over $960,000 previously awarded to DMC by NSF through the SBIR Phase I and II programs. The additional funding will support the ongoing commercialization efforts of DMC’s Dynamic Metabolic Control technology platform and will help accelerate the company’s commercialization efforts.

DMC is scaling up to be a multi-product biobased chemical company. The first product family to come to market in 2020 will be specialty amino acids for food and feed. Pipeline product families include a variety of compounds with market applications in nutrition, personal care, flavor and fragrance, and fine chemicals.
The highly competitive NSF SBIR program seeks to transform early-stage scientific discovery into societal and economic benefit by catalyzing private sector commercialization of technological innovations. 
“We are honored to receive the continued support of the National Science Foundation towards the commercialization of our biobased specialty products. The NSF has been a vital partner in DMC’s growth, providing financial support and validation of our technology and business approach.  The strong progress we have made with our projects and partners was instrumental in DMC receiving this supplemental funding from NSF,” said Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC.

Brand Perspectives
On Biomaterials


Download Now